Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Avidity Biosciences, a biopharmaceutical company specializing in RNA therapeutics, announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on May 20, 2024.
The Human Capital Management Committee granted stock option awards for 150,500 shares and 33,250 restricted stock units (RSUs) to seven new non-executive employees.
The stock options, priced at $29.24 per share, will vest over four years with 25% vesting after one year and the remainder vesting monthly.
RSUs will vest in four equal annual installments, contingent on continued employment.
These awards are part of the 2022 Employment Inducement Incentive Award Plan, targeting new employees as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Avidity Biosciences (Nasdaq: RNA) announced the appointment of Simona Skerjanec to its board of directors. Ms. Skerjanec brings nearly three decades of pharmaceutical experience, specializing in developing and launching therapies, and corporate strategy. Her roles at Roche, The Medicines Company, Eli Lilly, Pfizer, and Johnson & Johnson highlight her expertise in neurology, cardiology, and rare diseases. Avidity CEO Sarah Boyce emphasized the importance of Ms. Skerjanec’s experience in advancing Avidity's RNA therapeutic programs, including neuromuscular and precision cardiology. Ms. Skerjanec expressed her excitement to contribute to Avidity's mission of revolutionizing RNA therapeutics.
Avidity Biosciences reported their first-quarter 2024 financial results and recent highlights, including the initiation of a global Phase 3 trial for del-desiran in DM1, positive long-term del-desiran data showing disease progression reversal in DM1 patients, and a cash position of $915 million. The company also received Breakthrough Therapy designation from the FDA for del-desiran and announced positive data from their FSHD and DMD44 trials. They raised $400 million through an equity raise and plan to share more data from ongoing trials later in the year.
Avidity Biosciences, Inc. (Nasdaq: RNA) will participate in the BofA Securities 2024 Health Care Conference on May 15. The company focuses on RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™). The event will be live-streamed and archived on the company's website.
Avidity Biosciences, Inc. (Nasdaq: RNA) has received FDA Breakthrough Therapy designation for delpacibart etedesiran (AOC 1001) for treating Myotonic Dystrophy Type 1. The company is starting a global Phase 3 HARBOR study for del-desiran this quarter. Data from MARINA-OLE showed reversal of disease progression in DM1 patients. Del-desiran aims to address the root cause of DM1, a fatal neuromuscular disease with no approved treatments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.